

Edgar Filing: CHEMED CORP - Form 8-K

CHEMED CORP
Form 8-K
October 18, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported):
October 11, 2002

CHEMED CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

1-8351
(Commission File Number)

31-0791746
(I.R.S. Employer
Identification Number)

2600 Chemed Center, 255 East 5th Street, Cincinnati, OH
(Address of principal executive offices)

45202
(Zip Code)

Registrant's telephone number, including area code:
(513) 762-6900

ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS

On October 11, 2002, Patient Care Inc. (Patient Care), a wholly owned subsidiary of Chemed Corporation (Company), sold all of the issued and outstanding stock of National Home Care Inc. (NHC), a wholly owned subsidiary of Patient Care, to PCI Holding Corp. (PCI-H), a Delaware corporation. Immediately thereafter, the Company sold all of the issued and outstanding stock of Patient Care to PCI-A Holding Corp. (PCI-A), a Delaware corporation. PCI-H and PCI-A are owned by an investor group that includes Schroder Ventures Life Sciences Group, Oak Investment Partners, Prospect Partners and Salix Ventures.

The cash proceeds to the Company from the sale of Patient Care totaled \$57.5 million, of which \$5 million was placed in escrow pending settlement of specified contingencies. In addition, the Company received a senior subordinated note receivable (Note) in the amount of \$12.5 million and a common stock purchase warrant for the purchase of 2% of the outstanding stock of PCI-H. The Note is due October 11, 2007 and bears interest at the annual rate of 7.5% through September 30, 2004, 8.5% from October 1, 2004 through September 30, 2005 and 9.5% thereafter. The warrant has an estimated fair value of \$1.4 million.

Patient Care provides home-healthcare services primarily in the New York-New Jersey-Connecticut area. Services provided include skilled nursing; home health aide; physical, speech, occupational therapy; and medical social work. There is no material relationship between PCI-H, PCI-A, Patient Care, NHC, the Company, any of the Company's affiliates, any Company director or officer or any associate of any such directors or officers.

The proceeds will be used to fund future acquisitions and general corporate purposes.

The Company anticipates that a portion of the cash proceeds from this transaction will be used to retire borrowings under its revolving credit agreement with Bank One, N.A. At September 30, 1997 the Company had borrowings of \$25 million outstanding under this agreement. The balance of the proceeds will be available for the funding of future acquisitions and general corporate purposes.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(a) Financial Statements of Businesses Acquired.

Not applicable.

(b) Pro Forma Financial Information (Unaudited). The following assumptions have been made in preparing the unaudited Pro Forma Consolidated Statements of Operations of Chemed Corporation and Subsidiary Companies (Chemed) for the year ended December 31, 2001 and for the six months ended June 30, 2001 and 2002 and the unaudited Pro Forma Consolidated Balance Sheet of Chemed as of June 30, 2002:

- (i) For purposes of preparing the unaudited Pro Forma Condensed Consolidated Statements of Operations, the dispositions of NHC and Patient Care were assumed to have occurred at the beginning of each fiscal period presented.
- (ii) For purposes of preparing the unaudited Pro Forma Consolidated Balance Sheet, the dispositions of NHC and Patient Care were assumed to have occurred on June 30, 2002.

- (iii) The unaudited pro forma consolidated financial statements presented herein are shown for illustrative purposes only and are not necessarily indicative of the future financial position or future results of operations of Chemed, or of the financial position or results of operations that would have actually occurred had the transactions been in effect as of the date or for the periods presented.
- (iv) The unaudited pro forma consolidated financial statements should be read in conjunction with the historical financial statements and related notes of Chemed.

The unaudited pro forma consolidated financial statements of Chemed follow on the next page:

Edgar Filing: CHEMED CORP - Form 8-K

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET
 JUNE 30, 2002
 (in thousands except share and per share data)

	Adjustments Add/(Deduct)			Pro Forma
	Historical	Patient Care (a)	Other	
ASSETS				
Current Assets				
Cash and cash equivalents	\$ 11,456	\$ 458	\$ 52,071(b)	\$ 63,985
Accounts receivable less allowances of \$5,201 (pro forma \$4,281)	50,792	(35,998)		14,794
Inventories	10,070			10,070
Statutory deposits	12,282			12,282
Prepaid expenses	16,583	(2,286)		14,297
Total current assets	101,183	(37,826)	52,071	115,428
Other investments	37,692			37,692
Properties and equipment, at cost less accumulated depreciation of \$72,687 (pro forma \$63,957)	62,349	(12,360)		49,989
Identifiable intangible assets less accumulated amortization of \$8,426 (pro forma \$6,859)	3,685	(488)		3,197
Goodwill less accumulated amortization of \$35,541 (pro forma \$30,450)	161,852	(30,673)		131,179
Other assets	27,174	1,494	19,951(b)	48,619
Total Assets	\$ 393,935	\$ (79,853)	\$ 72,022	\$ 386,104
LIABILITIES				
Current liabilities				
Accounts Payable	\$ 9,097	\$ (1,588)	\$	\$ 7,509
Current portion of long-term debt	366			366
Income taxes	4,433	22	540(c)	4,995
Deferred contract revenue	21,202			21,202
Other current liabilities	46,676	(9,759)	2,450(c)	39,367
Total current liabilities	81,774	(11,325)	2,990(c)	73,439
Long-term debt	55,810			55,810
Other liabilities	26,545			26,545
Total Liabilities	164,129	(11,325)	2,990	155,794
MANDATORILY REDEEMABLE CONVERTIBLE PREFERRED SECURITIES OF THE CHEMED CAPITAL TRUST				
	14,186			14,186
STOCKHOLDERS EQUITY				
Capital stock authorized 15,000,000 shares \$1 par; issued 13,460,755 shares	13,461			13,461
Paid in capital	168,448			168,448
Retained earnings	146,240	(68,528)	69,032(b)	146,744
Treasury stock 3,665,835 shares, at cost	(112,568)			(112,568)
Unearned compensation	(5,480)			(5,480)
Deferred compensation payable in company stock	2,253			2,253

Edgar Filing: CHEMED CORP - Form 8-K

Accumulated other comprehensive income	4,205			4,205
Notes receivable for shares sold	(939)			(939)
	<u> </u>			<u> </u>
Total Stockholders' Equity	215,620	(68,528)	69,032	216,124
	<u> </u>			<u> </u>
Total Liabilities and Stockholders' Equity	\$ 393,935	\$ (79,853)	\$ 72,022	\$ 386,104
	<u> </u>			<u> </u>

-
- (a) Historical balance sheet of Patient Care
 - (b) Proceeds from sale of Patient Care
 - (c) Accrual of expenses and income taxes on sale of Patient Care

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS
 FOR THE YEAR ENDED DECEMBER 31, 2001
 (in thousands except share and per share data)

	Adjustments		Add/(Deduct)	Pro Forma
	Historical	Patient Care (a)		
Continuing Operations				
Service revenues and sales	\$ 477,116	\$ (139,208)	\$	\$ 337,908
Cost of services provided and cost of goods sold	295,477	(89,862)		205,615
General and administrative expenses	101,141	(44,769)		56,372
Selling and marketing expenses	45,569			45,569
Depreciation	16,109	(1,715)		14,394
Restructuring and similar expenses	26,126	(1,392)		24,734
Total costs and expenses	484,422	(137,738)		346,684
Income/(loss) from operations	(7,306)	(1,470)		(8,776)
Interest expense	(5,424)			(5,424)
Distributions on preferred securities	(1,113)			(1,113)
Other income net	3,780	1,208	938	5,926
Income/(loss) before income taxes	(10,063)	(262)	938	(9,387)
Income taxes	3,362	(264)	(328)	2,770
Income/(loss) from continuing operations	\$ (6,701)	\$ (526)	\$ 610	\$ (6,617)
Earnings/(Loss) Per Share				
Income/(loss) from continuing operations	\$ (0.69)			\$ (0.68)
Average number of shares outstanding	9,714			9,714
Diluted Earnings/(Loss) Per Share				
Income/(loss) from continuing operations	\$ (0.69)			\$ (0.68)
Average number of shares outstanding	9,714			9,714
Earnings Excluding Goodwill Amortization				
Income/(loss) from continuing operations	\$ (2,080)			\$ (2,729)
Earnings/(loss) per share				
Income/(loss) from continuing operations	\$ (0.21)			\$ (0.28)
Average number of shares outstanding	9,714			9,714
Diluted earnings/(loss) per share				
Income/(loss) from continuing operations	\$ (0.21)			\$ (0.28)
Average number of shares outstanding	9,714			9,714

(a) Historical income statement of Patient Care.

(b) Interest income on note receivable from the sale of Patient care, computed at 7.5% per annum.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS
 FOR THE SIX MONTHS ENDED JUNE 30, 2001
 (in thousands except share and per share data)

	Adjustments Add/(Deduct)			Pro Forma
	Historical	Patient Care (a)	Other (b)	
Continuing Operations				
Service revenues and sales	\$ 241,989	\$ (70,780)	\$	\$ 171,209
Cost of services provided and cost of goods sold	146,880	(45,066)		101,814
General and administrative expenses	50,972	(22,493)		28,479
Selling and marketing expenses	22,253			22,253
Depreciation	8,027	(859)		7,168
Total costs and expenses	228,132	(68,418)		159,714
Income/(loss) from operations	13,857	(2,362)		11,495
Interest expense	(2,952)			(2,952)
Distributions on preferred securities	(555)			(555)
Other income net	2,604	708	469	3,781
Income/(loss) before income taxes	12,954	(1,654)	469	11,769
Income taxes	(5,010)	359	(164)	(4,815)
Income/(loss) from continuing operations	\$ 7,944	\$ (1,295)	\$ 305	\$ 6,954
Earnings/(Loss) Per Share				
Income/(loss) from continuing operations	\$ 0.82			\$ 0.71
Average number of shares outstanding	9,737			9,737
Diluted Earnings/(Loss) Per Share				
Income/(loss) from continuing operations	\$ 0.80			\$ 0.70
Average number of shares outstanding	9,885			9,885
Earnings Excluding Goodwill Amortization				
Income/(loss) from continuing operations	\$ 10,258			\$ 8,901
Earnings/(loss) per share				
Income/(loss) from continuing operations	\$ 1.05			\$ 0.91
Average number of shares outstanding	9,737			9,737
Diluted earnings/(loss) per share				
Income/(loss) from continuing operations	\$ 1.04			\$ 0.90
Average number of shares outstanding	9,885			9,885

(a) Historical income statement of Patient Care.

(b) Interest income on note receivable from the sale of Patient care, computed at 7.5% per annum.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS
 FOR THE SIX MONTHS ENDED JUNE 30, 2002
 (in thousands except share and per share data)

	Adjustments Add/(Deduct)			Pro Forma
	Historical	Patient Care (a)	Other (b)	
Continuing Operations				
Service revenues and sales	\$ 233,604	\$ (73,669)	\$	\$ 159,935
Cost of services provided and cost of goods sold	140,643	(45,511)		95,132
General and administrative expenses	48,798	(23,724)		25,074
Selling and marketing expenses	22,869			22,869
Depreciation	7,990	(1,012)		6,978
Total costs and expenses	220,300	(70,247)		150,053
Income/(loss) from operations	13,304	(3,422)		9,882
Interest expense	(1,536)			(1,536)
Distributions on preferred securities	(541)			(541)
Other income net	3,049	493	469	4,011
Income/(loss) before income taxes	14,276	(2,929)	469	11,816
Income taxes	(5,035)	938	(164)	(4,261)
Income/(loss) from continuing operations	\$ 9,241	\$ (1,991)	\$ 305	\$ 7,555
Earnings/(Loss) Per Share				
Income/(loss) from continuing operations	\$ 0.94			\$ 0.77
Average number of shares outstanding	9,850			9,850
Diluted Earnings/(Loss) Per Share				
Income/(loss) from continuing operations	\$ 0.93			\$ 0.77
Average number of shares outstanding	10,274			10,274
Earnings Excluding Goodwill Amortization				
Income/(loss) from continuing operations	\$ 9,241			\$ 7,555
Earnings/(loss) per share				
Income/(loss) from continuing operations	\$ 0.94			\$ 0.77
Average number of shares outstanding	9,850			9,850
Diluted earnings/(loss) per share				
Income/(loss) from continuing operations	\$ 0.93			\$ 0.77
Average number of shares outstanding	10,274			10,274

(a) Historical income statement of Patient Care.

(b) Interest income on note receivable from the sale of Patient care, computed at 7.5% per annum.

(c) EXHIBITS

SK 601 Ref. No.	Description
2.1	Stock Purchase Agreement dated as of May 8, 2002 by and between PCI Holding Corp. and Chemed Corporation.
2.2	Amendment No. 1 to Stock Purchase Agreement dated as of October 11, 2002 by and among PCI Holding Corp., PCI-A Holding Corp. and Chemed Corporation.
2.3	Senior Subordinated Promissory Note dated as of October 11, 2002 by and among PCI Holding Corp. and Chemed Corporation.
2.4	Common Stock Purchase Warrant dated as of October 11, 2002 by and between PCI Holding Corp. and Chemed Corporation.
99.1	Press release, dated October 11, 2002.

CERTIFICATION AND SIGNATURES

The undersigned hereby certify that this report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, 15U.S.C. section 78(m) or 78(o)(d) and that information contained herein fairly presents, in all material respects, the financial condition and results of operations of Registrant.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CHEMED CORPORATION
(Registrant)

Dated: October 11, 2002

By /s/ Kevin J. McNamara

Kevin J. McNamara
(President and Chief Executive Officer)

Dated: October 11, 2002

By /s/ Timothy S. O Toole

Timothy S. O Toole
(Executive Vice President and Treasurer
Principal Financial Officer)

Dated: October 11, 2002

By /s/ Arthur V. Tucker, Jr.

Arthur V. Tucker, Jr.
(Vice President and Controller
Principal Accounting Officer)